Literature DB >> 22543429

Mitochondrial changes within axons in multiple sclerosis: an update.

Graham R Campbell1, Nobuhiko Ohno, Doug M Turnbull, Don J Mahad.   

Abstract

PURPOSE OF REVIEW: Here, we discuss the recent developments in axonal mitochondrial response to demyelination and remyelination in multiple sclerosis (MS), and following experimental demyelination as well as myelination. RECENT
FINDINGS: There is a gathering body of evidence implicating an energy-deficient state in the pathogenesis of MS, and mitochondrial defects have been the subject of a number of previous reviews. In myelinated axons within the central nervous system, over 90% of mitochondria are located within juxtaparanodal and internodal axoplasm. The electrogenic machinery, mitochondria and myelin form a triad that is disrupted in MS. The axonal mitochondrial content increases following demyelination and persists despite the residual inflammatory reaction subsiding to levels seen in control cases. The changes in axonal mitochondrial content following demyelination in MS and experimental demyelination in vivo and in vitro do not return to the levels in nondemyelinated and myelinated axons following remyelination.
SUMMARY: Understanding the mechanisms of axonal mitochondrial response to a disturbance in myelin and determining if certain aspects of the axonal mitochondrial response to demyelinated and remyelinated axons are beneficial may identify potential therapeutic targets for the progressive forms of MS.

Entities:  

Mesh:

Year:  2012        PMID: 22543429     DOI: 10.1097/WCO.0b013e3283533a25

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  10 in total

Review 1.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

Review 2.  SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.

Authors:  Vamshi K C Nimmagadda; Tapas K Makar; Krish Chandrasekaran; Avinash Rao Sagi; Jayanta Ray; James W Russell; Christopher T Bever
Journal:  J Neuroimmunol       Date:  2016-07-17       Impact factor: 3.478

3.  Coordination of mitophagy and mitochondrial biogenesis during ageing in C. elegans.

Authors:  Konstantinos Palikaras; Eirini Lionaki; Nektarios Tavernarakis
Journal:  Nature       Date:  2015-04-20       Impact factor: 49.962

Review 4.  OXPHOS mutations and neurodegeneration.

Authors:  Werner J H Koopman; Felix Distelmaier; Jan A M Smeitink; Peter H G M Willems
Journal:  EMBO J       Date:  2012-11-13       Impact factor: 11.598

5.  Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis.

Authors:  Iraj Ragerdi Kashani; Zahra Rajabi; Mohammad Akbari; Gholamreza Hassanzadeh; Alireza Mohseni; Mohammadtaha Kouchakinejad Eramsadati; Kheirollah Rafiee; Cordian Beyer; Markus Kipp; Adib Zendedel
Journal:  Exp Brain Res       Date:  2014-05-06       Impact factor: 1.972

Review 6.  Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.

Authors:  Giuseppe Scalabrino
Journal:  Biomedicines       Date:  2022-03-30

Review 7.  Oligodendroglia and neurotrophic factors in neurodegeneration.

Authors:  Andrew N Bankston; Mariana D Mandler; Yue Feng
Journal:  Neurosci Bull       Date:  2013-04-05       Impact factor: 5.203

Review 8.  Autophagy and Autophagy-Related Proteins in CNS Autoimmunity.

Authors:  Christian W Keller; Jan D Lünemann
Journal:  Front Immunol       Date:  2017-02-27       Impact factor: 7.561

Review 9.  Neurodegeneration in Multiple Sclerosis: The Role of Nrf2-Dependent Pathways.

Authors:  Paloma P Maldonado; Coram Guevara; Margrethe A Olesen; Juan Andres Orellana; Rodrigo A Quintanilla; Fernando C Ortiz
Journal:  Antioxidants (Basel)       Date:  2022-06-10

10.  Idebenone does not inhibit disability progression in primary progressive MS.

Authors:  Peter Kosa; Tianxia Wu; Jonathan Phillips; Mika Leinonen; Ruturaj Masvekar; Mika Komori; Alison Wichman; Mary Sandford; Bibiana Bielekova
Journal:  Mult Scler Relat Disord       Date:  2020-08-05       Impact factor: 4.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.